MedTrace Logo

Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer

NCT02666378 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-10-01

No results posted yet for this study

Summary

This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a method of detecting early signs of damage to the heart that can be associated with anthracycline-based chemotherapy for the treatment of breast cancer.

Conditions

Interventions

OTHER

Cardiac Magnetic Resonance Imaging (CMR)

Subjects will be recruited for observational cardiac magnetic resonance imaging.

OTHER

Echocardiogram (ECHO)

Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.

Sponsors & Collaborators

Principal Investigators

  • Reza Nezafat, Ph.D · Beth Israel Deaconess Medical Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2024-07-10
Completion
2024-07-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02666378 on ClinicalTrials.gov